Phenprobamate
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Phenprobamate is a skeletal muscle relaxant indicated in the treatment of pain caused by muscle spasms.
- Generic Name
- Phenprobamate
- DrugBank Accession Number
- DB13354
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 179.219
Monoisotopic: 179.094628663 - Chemical Formula
- C10H13NO2
- Synonyms
- Phenprobamate
- External IDs
- MH-532
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Pain Combination Product in combination with: Acetaminophen (DB00316) •••••••••••• •••••• Treatment of Pain •••••••••••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Phenprobamate. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Phenprobamate. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Phenprobamate. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Phenprobamate. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Phenprobamate. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image KUIFLEX 200 MG/200 MG FİLM KAPLI TABLET, 40 ADET Phenprobamate (200 mg) + Acetaminophen (200 mg) Tablet, film coated Oral ABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. 1989-02-03 Not applicable Turkey KUILIL 200 MG/200 MG FİLM TABLET, 40 TABLET Phenprobamate (200 mg) + Acetaminophen (200 mg) Tablet, film coated Oral EXELTIS İLAÇ SAN. VE TİC. A.Ş. 1964-10-05 Not applicable Turkey
Categories
- ATC Codes
- M03BA71 — Phenprobamate, combinations with psycholeptics
- M03BA — Carbamic acid esters
- M03B — MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
- M03 — MUSCLE RELAXANTS
- M — MUSCULO-SKELETAL SYSTEM
- M03BA — Carbamic acid esters
- M03B — MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
- M03 — MUSCLE RELAXANTS
- M — MUSCULO-SKELETAL SYSTEM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Not Available
- Direct Parent
- Benzene and substituted derivatives
- Alternative Parents
- Carboximidic acids and derivatives / Organopnictogen compounds / Organooxygen compounds / Imines / Hydrocarbon derivatives
- Substituents
- Aromatic homomonocyclic compound / Carboximidic acid derivative / Hydrocarbon derivative / Imine / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UJZ473TPS0
- CAS number
- 673-31-4
- InChI Key
- CAMYKONBWHRPDD-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H13NO2/c11-10(12)13-8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H2,11,12)
- IUPAC Name
- 3-phenylpropyl carbamate
- SMILES
- NC(=O)OCCCC1=CC=CC=C1
References
- General References
- External Links
- ChemSpider
- 4606
- BindingDB
- 66801
- ChEBI
- 31992
- ChEMBL
- CHEMBL1079576
- ZINC
- ZINC000001676954
- Wikipedia
- Phenprobamate
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 400 mg Tablet, film coated Oral 400 mg Tablet, film coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.514 mg/mL ALOGPS logP 1.77 ALOGPS logP 2.05 Chemaxon logS -2.5 ALOGPS pKa (Strongest Acidic) 15.69 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 52.32 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 50.06 m3·mol-1 Chemaxon Polarizability 19.58 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014l-6900000000-2cb3269745a3b29bcd27 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-2900000000-42b2fbc10c0798fb71d8 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-48f5aa5980ad3fcbaa97 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-066u-6900000000-fde769f7068cef55ec13 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-1476c6715380e4cac656 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-9100000000-d9ea58bf82587767ee44 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 146.5573959 predictedDarkChem Lite v0.1.0 [M-H]- 146.5189959 predictedDarkChem Lite v0.1.0 [M-H]- 134.99327 predictedDeepCCS 1.0 (2019) [M+H]+ 145.1384959 predictedDarkChem Lite v0.1.0 [M+H]+ 146.0922959 predictedDarkChem Lite v0.1.0 [M+H]+ 138.36641 predictedDeepCCS 1.0 (2019) [M+Na]+ 146.4688959 predictedDarkChem Lite v0.1.0 [M+Na]+ 146.5787959 predictedDarkChem Lite v0.1.0 [M+Na]+ 147.73741 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:40 / Updated at June 02, 2021 20:04